ImmuPharma Management
Management criteria checks 4/4
ImmuPharma's CEO is Tim McCarthy, appointed in Jul 2021, has a tenure of 2.83 years. total yearly compensation is £106.50K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 0.36% of the company’s shares, worth €32.97K. The average tenure of the management team and the board of directors is 2.3 years and 9.8 years respectively.
Key information
Tim McCarthy
Chief executive officer
UK£106.5k
Total compensation
CEO salary percentage | 100.0% |
CEO tenure | 2.8yrs |
CEO ownership | 0.4% |
Management average tenure | 2.3yrs |
Board average tenure | 9.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Jun 30 2023 | n/a | n/a | -UK£3m |
Mar 31 2023 | n/a | n/a | -UK£3m |
Dec 31 2022 | UK£107k | UK£107k | -UK£4m |
Sep 30 2022 | n/a | n/a | -UK£5m |
Jun 30 2022 | n/a | n/a | -UK£6m |
Mar 31 2022 | n/a | n/a | -UK£7m |
Dec 31 2021 | UK£575k | UK£287k | -UK£8m |
Sep 30 2021 | n/a | n/a | -UK£8m |
Jun 30 2021 | n/a | n/a | -UK£8m |
Mar 31 2021 | n/a | n/a | -UK£7m |
Dec 31 2020 | UK£260k | n/a | -UK£7m |
Sep 30 2020 | n/a | n/a | -UK£6m |
Jun 30 2020 | n/a | n/a | -UK£5m |
Mar 31 2020 | n/a | n/a | -UK£6m |
Dec 31 2019 | UK£260k | n/a | -UK£6m |
Sep 30 2019 | n/a | n/a | -UK£7m |
Jun 30 2019 | n/a | n/a | -UK£7m |
Mar 31 2019 | n/a | n/a | -UK£7m |
Dec 31 2018 | UK£260k | n/a | -UK£7m |
Sep 30 2018 | n/a | n/a | -UK£7m |
Jun 30 2018 | n/a | n/a | -UK£7m |
Mar 31 2018 | n/a | n/a | -UK£7m |
Dec 31 2017 | UK£260k | n/a | -UK£6m |
Compensation vs Market: Tim's total compensation ($USD133.64K) is below average for companies of similar size in the German market ($USD402.64K).
Compensation vs Earnings: Tim's compensation has been consistent with company performance over the past year.
CEO
Tim McCarthy (67 yo)
2.8yrs
Tenure
UK£106,500
Compensation
Mr. Timothy Paul McCarthy, XIV, also known as Tim, MBA, FCCA, is Independent Non-Executive Chairman at 4basebio PLC. He co-founded Alizyme PLC in 1995. Mr. McCarthy serves as the Chairman of ImmuPharma plc...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman & CEO | 2.8yrs | UK£106.50k | 0.36% £ 33.0k | |
COO & Director | 4.3yrs | UK£92.50k | 0.13% £ 11.6k | |
Head of Investor Relations & Non Executive Director | 12.3yrs | UK£48.00k | 0.38% £ 35.1k | |
Head of Clinical Development | no data | no data | no data | |
Chief Scientific Officer of ImmuPharma Biotech | 1.7yrs | no data | no data | |
Head of Clinical & Medical Affairs | 1.3yrs | no data | no data | |
CEO of ImmuPharma Biotec & Director | 1.7yrs | no data | 0.036% £ 3.3k |
2.3yrs
Average Tenure
58yo
Average Age
Experienced Management: 25I's management team is considered experienced (2.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman & CEO | 8.7yrs | UK£106.50k | 0.36% £ 33.0k | |
COO & Director | 2.8yrs | UK£92.50k | 0.13% £ 11.6k | |
Head of Investor Relations & Non Executive Director | 2.8yrs | UK£48.00k | 0.38% £ 35.1k | |
CEO of ImmuPharma Biotec & Director | less than a year | no data | 0.036% £ 3.3k | |
Member of Scientific Advisory Board | 10.8yrs | no data | no data | |
Member of Scientific Advisory Board | 10.8yrs | no data | no data | |
Member of Scientific Advisory Board | 10.8yrs | no data | no data | |
Member of Scientific Advisory Board | 10.8yrs | no data | no data | |
Member of Scientific Advisory Board | 10.8yrs | no data | no data | |
Senior independent Non-Executive Director | less than a year | no data | no data |
9.8yrs
Average Tenure
58yo
Average Age
Experienced Board: 25I's board of directors are considered experienced (9.8 years average tenure).